Scientists found that the experimental vaccine was more than 70% effective at preventing Lyme disease in a trial of nearly 10,000 volunteers.

When a Lyme-carrying tick slurps up blood from a vaccinated person, these anti-OspA antibodies are also ingested. And once inside the tick’s gut, the antibodies are intended to bind to the bacteria and prevent them, from leaving the tick at all, thus preventing infection.

Based on the trial’s primary endpoint, the vaccine’s potential effectiveness ranged from 15.8% to 93.5%, which was below the 20% lower bound that the companies had set as a goal.

Notably, in a separate analysis of the data, the vaccine did surpass the 20% lower range (the 95% confidence interval was between 21.7% and 93.9%).

Press Release Reported On: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate